"Novo Nordisk's Breakthrough Weight-Loss Pill Outperforms Ozempic in Clinical Trial"

Novo Nordisk's experimental weight-loss pill, amycretin, has shown promising early results in a small trial, with participants losing 13 percent of their body weight over three months, double the effectiveness of its existing drugs Ozempic and Wegovy. The pill, taken orally unlike the injections, mimics the gut hormone GLP-1 and another hormone called amylin. While the results have sent the company's shares soaring, experts caution that more research is needed to establish its long-term effectiveness and safety. The trial involved 16 participants, and further data from an injectable form of amycretin is expected next year.